# GLP Certificate holder MEDITOX

#### PRECLINICAL RESEARCH AND DEVELOPMENT

cardiology, diabetes, neurology, vaccines, ophthalmology


#### COMPREHENSIVE PRECLINICAL **TOXICOLOGICAL PROGRAM**

human and veterinary drugs, biological, medical devices, REACH


#### www.meditox.eu

#### ANIMAL MODELS OF SELECTED **HUMAN DISEASES**

CVS, neurodegenerative, ophthalmic, diabetes



non-human primates, dogs, rodents



MediTox s.r.o. Czech Republic e-mail: surova@meditox.eu www.meditox.eu



**CARDIOLOGY DISEASES** 


**HUNTINGTON'S DISEASE MODE** 

DIABETES / OBESITY MODEL

**OPHTHALMOLOGY DISEASES** 







per aspera ad astra



#### History

1951: Research Institute for Pharmacy and Biochemistry, Prague
250 drugs (29 original substances)
Pelentan, Kebuzon, Dosulepin, Metipranolol
Full chain of drug development

1999: Privatization and splitting off RIPB into several private companies - BioTest s.r.o. (branch of pre-clinical toxicology)

April 1, 2013: Change the brand to MediTox s.r.o.



#### Main actvities

#### Preclinical R&D

Cardiovascular disorders, diabetes, preclinical vaccine development neurodegenerative diseases, ophthalmic diseases, osteoarthrosis

#### Comprehensive toxicological program

Human & veterinary pharmaceuticals/biological, food additives, medical devices (PHARM) chemicals & agrochemicals (REACH)

#### Animal models of selected human diseases

Experimental IM, glaucoma, diabetes type II, chronic SCI, osteoarthrosis

#### Laboratory animal breeding

Non-human primates, dogs





#### Certification

Good Laboratory Practice Certificate OECD GLP [C(97)186 Final] Pharmaceuticals, medical devices and food additives (PHARMA)

Good Laboratory Practice Certificate OECD GLP [C(97)186 Final] Chemicals, agrochemicals (REACH)

Authorization for Using of Experimental Animals

The Central Committee for Animal Protection of the Ministry of Agriculture


Authorization for Breeding of Experimental Animals
The Central Committee for Animal Protection of the Ministry of Agriculture

**Approval for handling with GMO** in compliance with Act No. 153/2000 Coll.



### **Summary information**


#### **Structure of exprimental work**





### **Summary information**


#### **Structure of clients**





### **Summary information**

#### **Structure of clients**



per aspera ad astra



#### **R&D** projects - international

**FLUVAC** Live attenuated replication-defective influenza vaccine

Austria (AGBT), Germany, Russia, Slovenia, Czech Republic

ANTIFLU Innovative anti-influenza drugs exluding viral escape

Denmark, France, Germany (MPI), Hungary, Israel, United Kingdom, Czech Republic

**OSTEOGROW** Novel morphogenetic protein-6 biocompatible carrier device

Austria, Bosnia and Herzegovina, Croatia (UZ), Czech Republic, Sweden

**MOTIF** Micorbicide optimization through innovative formulation for

vaginal and rectal delivery

Czech Republic, France, Italy, United Kingdom (KCL)

**HELICOVAXOR** Development of an oral Helicobacter Pylori vaccine

Belgium, Czech Republic, France, Switzerland, United Kingdom (ICL)





#### Selected R&D projects - international

UNIVAC A "Universal" influenza vaccine though synthetic,

dendritic cell-targeted, self-replicating RNA Vaccines
Czech Republic, France, Germany, Norway, Russia, UK, Switzerland

MuleVaClin Clinical studies on a multivalent vaccine for human visceral

leisnmaniasis

Czech Republic, Italy, Spain, Switzerland



per aspera ad astra



#### **R&D** projects - national

**ODDC** Original Drug Development Center

IOCB AS CR, ICT, IEM AS CR, Institut of Physiology AS CR, Apigenex s.r.o., MediTox s.r.o.,

Quinta-Analytica s.r.o.

**BIOMEDTEST** Biomedical models of traumatic spinal cord injury and

neurodegenerative diseases in miniature pigs for testing of new

therapeutic approaches

Institut of Animal Physology & Genetics AS CR, MediTox s.r.o.








#### Collaboration within professional associations

**CzechBio** Association of Czech biotech companies

MedChemBio Cluster of medicinal chemistry and chemical biology



per aspera ad astra



#### Contract-based experimental services

**Genetic toxicology & cytotoxicity** 

General toxicology

(acute, sub-chronic, chronic)

Safety Pharmacology (CVS, CNS)

Immunogenicity/Immunotoxicity

Local effects (irritability, sensitization, implantation, local tolerance)

#### Non-clinical evaluation

- anticancer pharmaceuticals
- vaccines
- biotech-derived products
- fixed combinations

PK/TK, BA, BEQ studies
Biocompatibility of medical devices

in vitro (bacteria, mamalian cells), in vivo (rodents)

rodents, non-rodents

dogs, rats

rodents, non-rodents


in vitro, rodents, non-rodents

rodents, non-rodents

rodents, non-rodents



per aspera ad astra



### Contract-based experimental services

**Toxicity to reproduction** 

**Rodents** 

Carcinogenicity

**Rodents** 

**Biodistribution studies** 

Rodents, non-rodents

Screening reproduction toxicity

Prenatal developmental toxicity

One- and two-generation toxicity

Combined reproduction/toxicity studies

**Extended one-generation toxicity** 

**Carcinogenicity (including DRF)** 

Combined toxicity/carcinogenicity studies

Non-radiolabeled compounds

per aspera ad astra



#### Animal models of selected human diseases

**Diabetes** (type II - non-human primates)

Chronic glaucoma (dogs)

**Experimental myocardial infarct** (dogs, mini pigs)

Chronic traumatic spinal cord injury (mini pigs)

Acute contact dermatitis (mini pigs)

Influenza model (ferrets)


Osteoarthrosis (guinea pigs, rabbits)





#### Experimental model of diabetes, rhesus monkeys

- Most common in older, obese animals
- Period of obesity-associated insulin resistance initially with compensatory insulin secretion
- Pathological changes in pancreatic islets similar to those seen in human
- Changes in plasma lipid and lipoprotein concentrations and lipoprotein composition




per aspera ad astra



#### Experimental model of myocardial infarction, dog

- Left ventricular dysfunction induced by by ligation of the left coronary artery (myocardial ischemia) followed by heart reperfusion.
- Morphometric analysis of area at risk and area of infarction performed using Coomassie blue

Arteria coronaria occlusion 90-minute ischemia following 5-hour re-perfusion



Myocardial section (Coomassie blue injected into *arteria coronaria*):

Dark blue – intact myocardium

Red – ischemia zone

White - infarctation zone





#### Chronic traumatic spinal cord injury model, pig

- Computer-managed device providing strictly repeatable spinal cord injury, either in the thoracal


or lumbal region


- All essential reflexes (feeding, urination and defecation) preserved

- Long lasting survival of paraplegic animals









per aspera ad astra



#### Experimental chronic glaucoma, dogs

"More than 70 million people worldwide suffer from glaucoma. Glaukoma is leading cause of blindness."

Induced by intraocular injection of chymotripsine

**Revealing chracteristical clinical signs** 

- elevation of IOP
- corneal opacity
- dilated episcleral blood vessels at the corneal edge
- reduced or absent pupillary reflex
- uveitis.





per aspera ad astra



# Ferret model for safety and efficacy of influenza therapy

Ferrets (*Mustela putoria*) emulate numerous clinical features associated with human disease; this is especially the case with regard to influenza

Clinical and clinical laboratory features shared by humans and ferret model following virus

infection - Fever

- Nasal secretion
- Coughing
- Serum abnormalitires
- Weight loss and/or anorexia
- Lethargy
- Lymphopenia
- Transmission to susceptible contacts
- Hypercytokinemia
- Distribution of sialic acid in respiratory tract








### **Breeding of laboratory animals**

#### **Non-rodents**

Rhesus macaques (*Macaca mulatta,* monitored quality)
Beagle dogs (monitored quality)



per aspera ad astra

#### References

Amega Biotech, Argentina

Bharat Biotech, India

Bio-Assistance, Canada

Bioxodes, France

California Univ, USA

Celon Pharma, Poland

**CONTIPRO a.s., CR** 

CRONET-Sagl, Switzerland

**DECHRA Veterinary Products**, UK

**DelSiTech Ltd.**, Finland

EMS, Brazil

**Evestra**, Germany

Faraday, Inc., USAFATRO, Italy

Fusion Pharma, Russia

Gelesis Inc., USA

IOCB CAS, CZ

KRKA, Slovenia

Lesaffre, France

Mabion, Poland

Medicine Development, Australia

NovoNordisk, Denmark

Oxford University, UK

Rottapharm, Italy


**Sanofi Group** (Zentiva)

Sunpharma, India


Univ Hospital Basel, Switzerland

**Triveritas**, USA/UK

Vetcare Oy, Finland




#### Sequence of events during the project















GLP Certificate holder

#### **MEDITOX**

PRECLINICAL RESEARCH AND DEVELOPMENT

COMPREHENSIVE PRECLINICAL TOXICOLOGICAL PROGRAM

ANIMAL MODELS OF SELECTED HUMAN DISEASES

ACCREDITED BREEDING FACILITY FOR LABORATORY ANIMALS



www.meditox.eu



CARDIOLOGY DISEASES
HUNTINGTON'S DI SEASE MODEL
DIABETES / OBESITY MODEL
OPHTHALMOLOGY DISEASES

MediTox s.r.o.
Pod Zámkem 279, 281 25 Konárovice
Czech Republic
tel: +420 313 129 374

e-mail: surova@meditox.eu

